di-tert-butoxy-methane | 2568-93-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: di-tert-butoxy-methane
• 英文别名: formaldehyde di-tert-butylacetal；Formaldehyd-di-tert-butylacetal；Di-tert-butoxymethan；Di-tert.-butyl-formal；di-tert-butylcarbonic acid anhydride；Formaldehyd-di-tert.-butylacetal；Methane, di-tert-butoxy-；2-methyl-2-[(2-methylpropan-2-yl)oxymethoxy]propane
• CAS: 2568-93-6
• 化学式: C₉H₂₀O₂
• 分子量: 160.257
• InChiKey: PEVBHXMGGQHNIM-UHFFFAOYSA-N

物化性质

• 沸点：
  182-185 °C
• 密度：
  0.8306 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  di-tert-butoxy-methane 在 二叔丁基过氧化物 作用下， 以 氯苯 为溶剂， 生成 异丁烷 、 甲酸叔丁酯
  参考文献：
  名称：

  Rol'nik, L. Z.; Kalashnikov, S. M.; Pastushenko, E. V., Journal of Organic Chemistry USSR (English Translation), 1981, vol. 17, # 4, p. 614 - 618

  摘要：

  DOI：
• 作为产物：
  描述：

  氯甲基甲硫醚 、 potassium tert-butylate 生成 di-tert-butoxy-methane
  参考文献：
  名称：

  硫代甲氧基甲基六氯锑酸酯与叔丁醇钾和其他碱的反应

  摘要：

  从用叔丁醇钾处理硫代甲氧基甲基六氯锑酸酯（II）分离出的主要产物是3,5,5-三甲基-1,3-氧杂硫基六氯锑酸酯（V）。描述了旨在阐明该过程机理的实验，以及II与一些其他代表性亲核试剂的反应。

  DOI：

  10.1016/s0040-4020(01)91632-1

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS
  申请人：Kandula Mahesh

  公开号：US20150307446A1

  公开（公告）日：2015-10-29

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗粘膜炎的方法可以制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗与消化道内膜疼痛性炎症和溃疡相关的黏膜疾病。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH
  申请人：Kandula Mahesh

  公开号：US20150133533A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promotes secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗或预防咳嗽的方法可以制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射。这种组合物可用于治疗急性呼吸道感染、哮喘、痛风、纤维肌痛、促进受孕、促进呼吸系统中的次级粘膜分泌、肌肉松弛剂、过敏、哮喘、慢性阻塞性肺疾病、痉挛、呼吸和神经系统疾病。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150057347A1

  公开（公告）日：2015-02-26

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.

  该发明涉及公式I和公式II的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I或公式II化合物的药物组合物；以及用于治疗或预防炎症和脂质紊乱的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗高三酸甘油酯血症、脂肪肝、半胱氨酸症和炎症性疾病。
• CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
  申请人：Arvinas, Inc.

  公开号：US20180215731A1

  公开（公告）日：2018-08-02

  The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  该描述涉及cereblon E3连接酶结合化合物，包括包含相同成分的双功能化合物，这些化合物作为靶向泛素化的调节剂具有实用价值，尤其是抑制剂，可降解和/或以其他方式抑制根据本公开的双功能化合物。特别是，该描述提供了化合物，其一端含有与cereblon E3泛素连接酶结合的配体，另一端含有与目标蛋白结合的部分，使目标蛋白位于泛素连接酶附近以降解（和抑制）该蛋白。可以合成表现出广泛药理活性的化合物，与几乎所有类型的靶向多肽的降解/抑制一致。